Evobrutinib Fails to Beat Teriflunomide in Relapsing MS

(MedPage Today) -- WEST PALM BEACH, Fla. -- The investigational oral Bruton's tyrosine kinase (BTK) inhibitor evobrutinib failed to distinguish itself from teriflunomide (Aubagio) in two phase III trials of relapsing multiple sclerosis (MS) patients...
Source: MedPage Today Neurology - Category: Neurology Source Type: news